Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program

被引:4
|
作者
Price, Alex T. [1 ]
Schiff, Joshua P. [2 ,6 ]
Laugeman, Eric [2 ]
Maraghechi, Borna [3 ]
Schmidt, Matthew [2 ]
Zhu, Tong [2 ]
Reynoso, Francisco [2 ]
Hao, Yao [2 ]
Kim, Taeho [2 ]
Morris, Eric [2 ]
Zhao, Xiaodong [2 ]
Hugo, Geoffrey D. [2 ]
Vlacich, Gregory [2 ]
DeSelm, Carl J. [2 ]
Samson, Pamela P. [2 ]
Baumann, Brian C. [4 ]
Badiyan, Shahed N. [5 ]
Robinson, Clifford G. [2 ]
Kim, Hyun [2 ]
Henke, Lauren E. [1 ,7 ]
机构
[1] Case Western Reserve Univ, Univ Hosp, Dept Radiat Oncol, Cleveland, OH USA
[2] Washington Univ, Sch Med St Louis, Dept Radiat Oncol, St Louis, MO USA
[3] City Hope Orange Cty, Dept Radiat Oncol, Irvine, CA USA
[4] Springfield Clin, Dept Radiat Oncol, Springfield, IL USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX USA
[6] Washington Univ, Sch Med, Dept Radiat Oncol, 4921 Parkview Pl,Campus Box 8224, St Louis, MO 63110 USA
[7] Case Western Reserve Univ, Univ Hosp, Dept Radiat Oncol, 11100 Euclid Ave, Cleveland, OH 44106 USA
关键词
Image -guided radiotherapy; Adaptive radiotherapy; Stereotactic body radiotherapy; MRI-guided radiotherapy; RADIATION-THERAPY SMART; PHASE-I TRIAL; IMPLEMENTATION; MALIGNANCIES; OUTCOMES; SYSTEM;
D O I
10.1016/j.ctro.2023.100661
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Our institution was the first in the world to clinically implement MR-guided adaptive radiotherapy (MRgART) in 2014. In 2021, we installed a CT-guided adaptive radiotherapy (CTgART) unit, becoming one of the first clinics in the world to build a dual-modality ART clinic. Herein we review factors that lead to the devel-opment of a high-volume dual-modality ART program and treatment census over an initial, one-year period.Materials and Methods: The clinical adaptive service at our institution is enabled with both MRgART (MRIdian, ViewRay, Inc, Mountain View, CA) and CTgART (ETHOS, Varian Medical Systems, Palo Alto, CA) platforms. We analyzed patient and treatment information including disease sites treated, radiation dose and fractionation, and treatment times for patients on these two platforms. Additionally, we reviewed our institutional workflow for creating, verifying, and implementing a new adaptive workflow on either platform.Results: From October 2021 to September 2022, 256 patients were treated with adaptive intent at our institution, 186 with MRgART and 70 with CTgART. The majority (106/186) of patients treated with MRgART had pancreatic cancer, and the most common sites treated with CTgART were pelvis (23/70) and abdomen (20/70). 93.0% of treatments on the MRgART platform were stereotactic body radiotherapy (SBRT), whereas only 72.9% of treatments on the CTgART platform were SBRT. Abdominal gated cases were allotted a longer time on the CTgART platform compared to the MRgART platform, whereas pelvic cases were allotted a shorter time on the CTgART platform when compared to the MRgART platform. Our adaptive implementation technique has led to six open clinical trials using MRgART and seven using CTgART.Conclusions: We demonstrate the successful development of a dual platform ART program in our clinic. Ongoing efforts are needed to continue the development and integration of ART across platforms and disease sites to maximize access and evidence for this technique worldwide.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Clinical Results of MR-guided stereotactic Radiotherapy of Liver Metastases
    Weykamp, Fabian
    Katsigiannopulos, Efthimios
    Regnery, Sebastian
    Hoegen, Philipp
    Renkamp, C. Katharina
    Rippke, Carolin
    Buchele, Carolin
    Lang, Kristin
    Liermann, Jakob
    Meixner, Eva
    Koenig, Laila
    Sandrini, Elisabetta
    Debus, Juergen
    Klueter, Sebastian
    Hoerner-Rieber, Juliane
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 : S142 - S142
  • [42] A Simple Adaptive Planning Workflow for MR-Guided Radiotherapy of Prostate Cancer
    Chen, X.
    Paulson, E.
    Ahunbay, E.
    Omari, E.
    Hall, W.
    Lawton, C.
    Straza, M.
    Li, X.
    MEDICAL PHYSICS, 2021, 48 (06)
  • [43] Target Definition in MR-Guided Adaptive Radiotherapy for Head and Neck Cancer
    de Ridder, Mischa
    Raaijmakers, Cornelis P. J.
    Pameijer, Frank A.
    de Bree, Remco
    Reinders, Floris C. J.
    Doornaert, Patricia A. H.
    Terhaard, Chris H. J.
    Philippens, Marielle E. P.
    CANCERS, 2022, 14 (12)
  • [44] Assessment of Dose Accuracy of Bulk Synthetic CT in MR-Guided Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
    Ding, S.
    Liu, H.
    Wang, B.
    Li, Y.
    Liu, B.
    Huang, X.
    MEDICAL PHYSICS, 2021, 48 (06)
  • [45] Automated Treatment Planning for adaptive MR-guided Radiotherapy of Prostate Cancer
    Tengler, B.
    Hagmueller, M.
    Kuenzel, L. A.
    Nachbar, M.
    Moennich, D.
    Boeke, S.
    Gani, C.
    Zips, D.
    Thorwarth, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S17 - S17
  • [46] Dosimetric Analyses of Stereotactic MR-Guided Adaptive Radiotherapy for Kidney Tumors
    Hsu, S.
    Han, Z.
    Sudhyadhom, A.
    Hu, Y.
    Mak, R.
    Huynh, M.
    Van Dams, R.
    Tanguturi, S.
    Venkatachalam, V.
    Cagney, D.
    Leeman, J.
    MEDICAL PHYSICS, 2022, 49 (06) : E762 - E763
  • [47] Technical Challenges of Real-Time Adaptive MR-Guided Radiotherapy
    Thorwarth, Daniela
    Low, Daniel A.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [48] MR-Guided Radiotherapy of Head and Neck Cancers: Adaptive Planning Strategies
    Dogan, N.
    Padgett, K.
    Duffy, M.
    Samuels, M.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S907 - S907
  • [49] Changes in Prostate Volume and Dosimetry with Stereotactic MR-Guided Adaptive Radiotherapy
    Huynh, E.
    Williams, C.
    Han, Z.
    Singer, L.
    Huynh, M.
    Mak, R.
    Cagney, D.
    Leeman, J.
    MEDICAL PHYSICS, 2021, 48 (06)
  • [50] Feasibility of neurovascular sparing MR-guided adaptive radiotherapy for prostate cancer
    Teunissen, F.
    Wortel, R.
    Hes, J.
    Willigenburg, T.
    de Boer, J.
    Meijer, R.
    van Melick, H.
    Verkooijen, H.
    van Zyp, J. van der Voort
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1126 - S1127